Antitussive effect of the leukotriene receptor antagonist zafirlukast in subjects with cough-variant asthma

Research output: Contribution to journalArticle

120 Citations (Scopus)

Abstract

Cough-variant asthma (CVA) occurs in a subgroup of asthmatics whose sole or predominant respiratory symptom is cough. Although bronchodilators are often sufficient to treat CVA, refractory cough may require therapy with inhaled or systemic corticosteroids. In a randomized, double-blind, placebo-controlled, crossover study, we examined the effect of a 14-day course of the leukotriene receptor antagonist zafirlukast on subjective cough score and cough-reflex sensitivity to inhaled capsaicin in eight subjects with CVA refractory to inhaled beta agonists, and in five subjects refractory to inhaled corticosteroids. Seven of eight subjects experienced significant subjective and objective improvement in cough after treatment with zafirlukast. Mean (± SEM) cough score improved from 7.75 ± 0.56 to 3.25 ± 0.84 (p = 0.0006). Cough sensitivity to capsaicin was suppressed by zafirlukast in all subjects. Patients with CVA may represent a distinct subgroup of asthmatics whose afferent cough receptors within the respiratory epithelium are hypersensitive relative to those of patients with the typical form of asthma. Zafirlukast appears to be particularly effective in treating CVA by inhibiting the sensitivity of these receptors. Leukotriene receptor antagonists may offer an alternative to corticosteroids for the treatment of CVA refractory to inhaled bronchodilators.

Original languageEnglish (US)
Pages (from-to)291-297
Number of pages7
JournalJournal of Asthma
Volume39
Issue number4
DOIs
StatePublished - 2002

Fingerprint

Antitussive Agents
Leukotriene Antagonists
Cough
Asthma
Adrenal Cortex Hormones
Capsaicin
Bronchodilator Agents
zafirlukast
Respiratory Mucosa

Keywords

  • Asthma
  • Capsaicin
  • Cough
  • Cough-Variant asthma
  • Leukotriene receptor antagonists
  • Leukotrienes
  • Zafirlukast

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

@article{4ebb503a42cc4710bdcbd8989f5dfe32,
title = "Antitussive effect of the leukotriene receptor antagonist zafirlukast in subjects with cough-variant asthma",
abstract = "Cough-variant asthma (CVA) occurs in a subgroup of asthmatics whose sole or predominant respiratory symptom is cough. Although bronchodilators are often sufficient to treat CVA, refractory cough may require therapy with inhaled or systemic corticosteroids. In a randomized, double-blind, placebo-controlled, crossover study, we examined the effect of a 14-day course of the leukotriene receptor antagonist zafirlukast on subjective cough score and cough-reflex sensitivity to inhaled capsaicin in eight subjects with CVA refractory to inhaled beta agonists, and in five subjects refractory to inhaled corticosteroids. Seven of eight subjects experienced significant subjective and objective improvement in cough after treatment with zafirlukast. Mean (± SEM) cough score improved from 7.75 ± 0.56 to 3.25 ± 0.84 (p = 0.0006). Cough sensitivity to capsaicin was suppressed by zafirlukast in all subjects. Patients with CVA may represent a distinct subgroup of asthmatics whose afferent cough receptors within the respiratory epithelium are hypersensitive relative to those of patients with the typical form of asthma. Zafirlukast appears to be particularly effective in treating CVA by inhibiting the sensitivity of these receptors. Leukotriene receptor antagonists may offer an alternative to corticosteroids for the treatment of CVA refractory to inhaled bronchodilators.",
keywords = "Asthma, Capsaicin, Cough, Cough-Variant asthma, Leukotriene receptor antagonists, Leukotrienes, Zafirlukast",
author = "Dicpinigaitis, {Peter Vytautas} and Dobkin, {Jay B.} and Joseph Reichel",
year = "2002",
doi = "10.1081/JAS-120002285",
language = "English (US)",
volume = "39",
pages = "291--297",
journal = "Journal of Asthma",
issn = "0277-0903",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Antitussive effect of the leukotriene receptor antagonist zafirlukast in subjects with cough-variant asthma

AU - Dicpinigaitis, Peter Vytautas

AU - Dobkin, Jay B.

AU - Reichel, Joseph

PY - 2002

Y1 - 2002

N2 - Cough-variant asthma (CVA) occurs in a subgroup of asthmatics whose sole or predominant respiratory symptom is cough. Although bronchodilators are often sufficient to treat CVA, refractory cough may require therapy with inhaled or systemic corticosteroids. In a randomized, double-blind, placebo-controlled, crossover study, we examined the effect of a 14-day course of the leukotriene receptor antagonist zafirlukast on subjective cough score and cough-reflex sensitivity to inhaled capsaicin in eight subjects with CVA refractory to inhaled beta agonists, and in five subjects refractory to inhaled corticosteroids. Seven of eight subjects experienced significant subjective and objective improvement in cough after treatment with zafirlukast. Mean (± SEM) cough score improved from 7.75 ± 0.56 to 3.25 ± 0.84 (p = 0.0006). Cough sensitivity to capsaicin was suppressed by zafirlukast in all subjects. Patients with CVA may represent a distinct subgroup of asthmatics whose afferent cough receptors within the respiratory epithelium are hypersensitive relative to those of patients with the typical form of asthma. Zafirlukast appears to be particularly effective in treating CVA by inhibiting the sensitivity of these receptors. Leukotriene receptor antagonists may offer an alternative to corticosteroids for the treatment of CVA refractory to inhaled bronchodilators.

AB - Cough-variant asthma (CVA) occurs in a subgroup of asthmatics whose sole or predominant respiratory symptom is cough. Although bronchodilators are often sufficient to treat CVA, refractory cough may require therapy with inhaled or systemic corticosteroids. In a randomized, double-blind, placebo-controlled, crossover study, we examined the effect of a 14-day course of the leukotriene receptor antagonist zafirlukast on subjective cough score and cough-reflex sensitivity to inhaled capsaicin in eight subjects with CVA refractory to inhaled beta agonists, and in five subjects refractory to inhaled corticosteroids. Seven of eight subjects experienced significant subjective and objective improvement in cough after treatment with zafirlukast. Mean (± SEM) cough score improved from 7.75 ± 0.56 to 3.25 ± 0.84 (p = 0.0006). Cough sensitivity to capsaicin was suppressed by zafirlukast in all subjects. Patients with CVA may represent a distinct subgroup of asthmatics whose afferent cough receptors within the respiratory epithelium are hypersensitive relative to those of patients with the typical form of asthma. Zafirlukast appears to be particularly effective in treating CVA by inhibiting the sensitivity of these receptors. Leukotriene receptor antagonists may offer an alternative to corticosteroids for the treatment of CVA refractory to inhaled bronchodilators.

KW - Asthma

KW - Capsaicin

KW - Cough

KW - Cough-Variant asthma

KW - Leukotriene receptor antagonists

KW - Leukotrienes

KW - Zafirlukast

UR - http://www.scopus.com/inward/record.url?scp=0036094767&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036094767&partnerID=8YFLogxK

U2 - 10.1081/JAS-120002285

DO - 10.1081/JAS-120002285

M3 - Article

VL - 39

SP - 291

EP - 297

JO - Journal of Asthma

JF - Journal of Asthma

SN - 0277-0903

IS - 4

ER -